Your browser doesn't support javascript.
loading
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
Allahyari, Abolghasem; Ehsanpour, Ali; Najafi, Behrouz; Ansarinejad, Nafiseh; Mehrzad, Valiollah; Kalantari, Behjat; Raafat, Jahangir; Ghadiany, Mojtaba; Shahi, Farhad; Gharib, Behrooz; Moazed, Vahid; Khosravi, Adnan; Mirpour, Mir Hossein; Salari, Sina; Mortazavizadeh, Seyedmohammadreza; Nekoyi, Amirabbas; Khani, Mohsen; Sadeghi, Alireza; Gharib, Sirus; Bary, Alireza; Mirzania, Mehrzad; Haghighat, Shirin; Razavi, Seyed Mohsen; Emami, Seyed Amir Hossein; Hosseinzadeh, Mehran; Mirbolouk, Mahdi; Sadighi, Sanambar; Shahrasbi, Abdolali; Esfahani, Ali; Gity, Masoumeh; Anjidani, Nassim; Kafi, Hamidreza; Najafi, Safa.
Afiliación
  • Allahyari A; Hematology Oncology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ehsanpour A; Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Najafi B; Hematology and Oncology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Science, Razi Hospital, Rasht, Iran.
  • Ansarinejad N; Department of Hematology & Oncology, Iran University of Medical Sciences, Tehran, Iran.
  • Mehrzad V; Hematology and Oncology Department, Isfahan Medical School, Isfahan, Iran.
  • Kalantari B; Hematology & Oncology, Department of Internal Medicine, School of Medicine, Shahid Bahonar Hospital, Kerman University of Medical Sciences, Kerman, Iran.
  • Raafat J; Mehrad Hospital, Tehran, Iran.
  • Ghadiany M; Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Shahi F; Department of Hematology and Medical Oncology, Breast Disease Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, TUMS, Tehran, Iran.
  • Gharib B; Department of Medical Oncology & Hematology, Naft Hospital, Tehran, Iran.
  • Moazed V; Hematology & Oncology Kerman University of Medical Sciences, Kerman, Iran.
  • Khosravi A; Hematology & Oncology, Department of Adult Hematology & Oncology, School of Medicine, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Dr. Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mirpour MH; Medical Oncology Guilan University of Medical Sciences, Razi Hospital, Fuman, Iran.
  • Salari S; Medical Oncology, Hematology Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mortazavizadeh S; Hematology/Oncology Yazd Azad University, Yazd, Iran.
  • Nekoyi A; Department of Hematology and Medical Oncology, Seyyed-al-shohada Hospital, Esfahan University of Medical Sciences, Tehran, Iran.
  • Khani M; Medicine Saba Oncology Clinic, Isfahan, Iran.
  • Sadeghi A; Department of Hematology-Oncology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Gharib S; Hematology, Oncology Department of Internal Medicine, Guilan University of Medical Sciences, Guilan, Iran.
  • Bary A; Department of Hematology & Oncology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mirzania M; Department of Hematology and Medical Oncology, Cancer Research Center, Cancer Institute of Iran, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Haghighat S; Hematology Research Center, Hematology and Medical Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Razavi SM; Iran Medical Science University, Tehran, Iran.
  • Emami SAH; Medical Oncology, Cancer Institute, Imam Khomeini Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Hosseinzadeh M; Hematology, Oncology Department of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Mirbolouk M; Hazrat Rasol Hospital Rasht, Gilan, Iran.
  • Sadighi S; Internal Medicine Group TUMS Faculty of Cancer Institute of Iran, Tehran, Iran.
  • Shahrasbi A; Bouali Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Esfahani A; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Gity M; Advanced Diagnostic and Interventional Radiology Research Center, Breast Disease Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Anjidani N; Medical Department, Orchid Pharmed Company, Tehran, Iran.
  • Kafi H; Medical Department, Orchid Pharmed Company, Tehran, Iran.
  • Najafi S; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. Safa3n@yahoo.com.
BMC Cancer ; 22(1): 960, 2022 Sep 07.
Article en En | MEDLINE | ID: mdl-36071409
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Biosimilares Farmacéuticos Tipo de estudio: Clinical_trials / Guideline Límite: Female / Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Irán
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Biosimilares Farmacéuticos Tipo de estudio: Clinical_trials / Guideline Límite: Female / Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Irán